Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer
2018 ◽
Vol 104
◽
pp. 21-31
◽
2011 ◽
Vol 41
(5)
◽
pp. 593-599
◽
2020 ◽
2020 ◽
2016 ◽
Vol 32
(2)
◽
pp. 385-394
◽